BM8 fundamentals
BIOMARIN PHARMA financial statements, including revenue, expenses, and profit
The total revenue of BM8 for the last quarter is 670.45 M CHF, and it's 6.57% higher compared to the previous quarter. The net income of Q4 24 is 113.47 M CHF.
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
0.00
170.00 M
340.00 M
510.00 M
680.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: CHF
Q1 '17
Mar 2017
Q2 '17
Jun 2017
Q3 '17
Sep 2017
Q4 '17
Dec 2017
Q1 '18
Mar 2018
Q2 '18
Jun 2018
Q3 '18
Sep 2018
Q4 '18
Dec 2018
Q1 '19
Mar 2019
Q2 '19
Jun 2019
Q3 '19
Sep 2019
Q4 '19
Dec 2019
Q1 '20
Mar 2020
Q2 '20
Jun 2020
Q3 '20
Sep 2020
Q4 '20
Dec 2020
Q1 '21
Mar 2021
Q2 '21
Jun 2021
Q3 '21
Sep 2021
Q4 '21
Dec 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
Q4 '24
Dec 2024
TTM
Total revenueYoY growth
542.84 M
+14.42%
532.46 M
+5.49%
536.45 M
+10.83%
543.81 M
+14.02%
586.33 M
+8.01%
637.11 M
+19.65%
629.11 M
+17.27%
670.45 M
+23.29%
2.58 B
−130.23 M
−128.67 M
−128.56 M
−126.89 M
−125.83 M
−130.14 M
−163.95 M
−132.41 M
−566.25 M
Gross profitYoY growth
412.61 M
+17.22%
403.79 M
+8.52%
407.89 M
+15.40%
416.92 M
+20.93%
460.51 M
+11.61%
506.97 M
+25.55%
465.16 M
+14.04%
538.05 M
+29.05%
2.01 B
−357.26 M
−352.96 M
−386.99 M
−371.74 M
−388.72 M
−413.95 M
−334.61 M
−412.61 M
−1.58 B
Operating incomeYoY growth
55.36 M
+131.88%
50.84 M
+71.68%
20.90 M
—
45.18 M
—
71.79 M
+29.69%
93.01 M
+82.96%
130.55 M
+524.61%
125.44 M
+177.63%
431.59 M
−3.40 M
12.57 M
17.25 M
−28.91 M
23.42 M
25.78 M
−16.62 M
28.63 M
60.44 M
Pretax incomeYoY growth
51.96 M
−58.06%
63.41 M
+90.28%
38.15 M
—
16.27 M
—
95.22 M
+83.25%
118.80 M
+87.34%
113.93 M
+198.65%
154.07 M
+846.81%
492.03 M
−5.41 M
−13.23 M
−1.18 M
882.35 K
−15.23 M
−22.44 M
−24.03 M
−40.59 M
−104.36 M
46.55 M
50.18 M
36.97 M
17.15 M
79.98 M
96.35 M
89.90 M
113.47 M
387.67 M
Net incomeYoY growth
46.55 M
−58.26%
50.18 M
+89.72%
36.97 M
—
17.15 M
—
79.98 M
+71.80%
96.35 M
+92.00%
89.90 M
+143.18%
113.47 M
+561.48%
387.67 M
46.55 M
51.02 M
36.97 M
17.15 M
82.48 M
98.84 M
91.45 M
115.14 M
396.03 M
Basic earnings per share (Basic EPS)YoY growth
0.25
−58.87%
0.27
+87.06%
0.20
—
0.09
—
0.42
+69.80%
0.51
+89.78%
0.47
+140.41%
0.60
+553.81%
2.04
Diluted earnings per share (Diluted EPS)YoY growth
0.24
−58.15%
0.26
+85.40%
0.19
—
0.09
—
0.41
+72.82%
0.49
+88.39%
0.46
+139.91%
0.59
+555.04%
2.00
186.67 M
187.95 M
188.22 M
188.48 M
188.87 M
190.11 M
190.43 M
190.69 M
—
194.36 M
195.00 M
191.17 M
191.84 M
199.26 M
200.50 M
197.15 M
196.58 M
—
EBITDAYoY growth
79.54 M
+61.94%
73.60 M
+36.86%
44.42 M
+733.25%
67.80 M
—
96.46 M
+21.27%
116.80 M
+58.70%
146.66 M
+230.19%
146.88 M
+116.64%
519.16 M
EBITYoY growth
55.36 M
+131.88%
50.84 M
+71.68%
20.90 M
—
45.18 M
—
71.79 M
+29.69%
93.01 M
+82.96%
130.55 M
+524.61%
125.44 M
+177.63%
431.59 M
−487.48 M
−481.62 M
−515.55 M
−498.63 M
−514.54 M
−544.10 M
−498.56 M
−545.01 M
−2.15 B